All manuscripts must be submitted online through the online submission system (https://www.editorialmanager.com/jmenopausalmed/default2.aspx).This website also provides an opportunity to track the progress of your manuscript through the peer-review process. If you have any questions, please contact:

Editor-in-chief

Jung Ryeol Lee, M.D., Ph.D.

Editorial Office

The Korean Society of Menopause
Department of Obstetrics and Gynecology
73 Inchon-ro, Seongbuk-gu, Seoul 02841, Republic of Korea
Tel: +82-2-920-5310, Fax: +82-2-921-5357
E-mail: ksm1992@empas.com
Web: https://www.koreanmenopause.or.kr/

All manuscripts should be prepared in strict adherence to the research and publication ethics guidelines recommended by the Council of Science Editors (CSE, http://www.councilscienceeditors.org/), International Committee of Medical Journal Editors (ICMJE, http://www.icmje.org/), World Association of Medical Editors (WAME, http://www.wame.org/), and the Korean Association of Medical Journal Editors (KAMJE, https://www.kamje.or.kr/). The Journal of Menopausal Medicine (JMM) will follow the flowchart established by the Committee on Publication Ethics (COPE, http://publicationethics.org/resources/flowcharts) for settlement of any alleged misconduct.

Registration of the Clinical Research and Data Sharing Policy
Any research that deals with clinical trial should be registered with the primary national clinical trial registration site such as http://cris.nih.go.kr/cris/index.jsp, or other sites accredited by World Health Organization or ICMJE (http://www.icmje.org/recommendations/browse/publishing-and-editorial-issues/clinical-trial-registration.html). This journal follows the data sharing policy described in “Data Sharing Statements for Clinical Trials: A Requirement of the International Committee of Medical Journal Editors.” The ICMJE’s policy regarding trial registration is explained at http://www.icmje.org/recommendations/browse/publishing-and-editorial-issues/clinical-trial-registration.html. If the data sharing plan changes after registration, this should be reflected in the statement submitted and published with the manuscript and updated in the registry record.

Statement of Informed Consent
Copies of written informed consent and institutional review board (IRB) approval for clinical research should be kept. If necessary, the editor or reviewers may request copies of these documents to resolve questions regarding IRB approval and study conduct.

Statement of Human and Animal Rights
Clinical research should be performed in accordance with the Ethical Principles for Medical Research Involving Human Subjects, as outlined in the Helsinki Declaration of 1975 (available from: https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-formedical-research-involving-human-subjects/). For animal subjects, the research should be performed in accordance with the guidelines set forth by the National or Institutional Guide for the Care and Use of Laboratory Animals, and the ethical treatment of all experimental animals should be maintained. Animal experiments must be reviewed by an appropriate committee (institutional animal care use committee, IACUC) for the care and use of animals.

Authorship
Authorship credit should be assigned on the basis of the following: 1) substantial contributions to study conception and design, acquisition of data, or analysis and interpretation of data; 2) drafting the article or revising it critically for important intellectual content; 3) final approval of the version to be published; and 4) agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. All co-authors should meet these four conditions. If the number of authors is greater than six, there should be a list of each author’s role in the submitted paper. After the initial submission of a manuscript, any changes, whatsoever, in authorship (adding author(s), deleting author(s), or re-arranging the order of authors) must be explained by a letter to the editor from all the concerned authors. This letter must be signed by all the authors on the paper. Additionally, copyright assignment must be completed by every author.

Originality and Duplicate Publication
All submitted manuscripts should be original and should not be under consideration for publication by any other scientific journals for publication at the same time. Any part of the accepted manuscript should not be duplicated in any other scientific journal without the explicit permission of the Editorial Board. Duplication will be checked using CrossCheck (https://app.ithenticate.com/) or eTBLAST (http://etest.vbi.vt.edu/etblast3) prior to submission. If duplicate publication related to the papers of this journal is detected, the manuscripts may be rejected, the authors will be announced in the journal, and their institutes will be informed. There may also be additional penalties for the authors. A letter of permission is required for any and all material previously published. It is the responsibility of the author to request permission from the publisher for any material being reproduced. This requirement applies to text, illustrations, figures, and tables.

Secondary Publication
It is possible to republish manuscripts if they satisfy the conditions of secondary publication set forth by the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals (http://www.icmje.org/recommendations/).

Conflict of Interest
The corresponding author of an article is asked to inform the editor of the authors’ potential conflicts of interest, which might influence their interpretation of data. A potential conflict of interest should be disclosed in the cover letter even when the authors are confident that their judgments have not been influenced in preparing the manuscript. Such conflicts may be financial support or private connections to pharmaceutical companies, political pressure from interest groups, or academic problems. The disclosure form is same as the ICMJE Conflict of Interest form (http://www.icmje.org/conflicts-of-interest/). The editor will decide whether the information regarding the potential conflict will be included in the published paper. Before publishing such information, the editor will consult with the corresponding author. In particular, all sources of funding for a study should be explicitly stated. JMM requests referees to inform the editor of any conflict of interest before accepting a request to review a particular manuscript.

All manuscripts will be evaluated by three peer reviewers who are selected by the editors. The acceptance criteria for all papers are based on the quality and originality of the research and its clinical and scientific significance. An initial decision will normally be made within 4 weeks after the agreement of review by the reviewers, and the reviewers’ comments will then be sent to the corresponding author(s).
Revised manuscripts must be submitted online by the corresponding author(s). The corresponding author must indicate the alterations that have been made in response to the reviewers’ comments item by item in a response letter and submit the original file with changes tracked. Failure to resubmit the revised manuscript within 60 days after the editorial decision will be regarded as a withdrawal.

The purpose of the proof is to check for typesetting or conversion errors as well as the completeness and accuracy of the text, tables, and figures. Substantial changes in content are not permitted without the approval of the editor. Proofs must be checked carefully and corrections returned within 24 to 48 hours of receipt, as requested in the cover letter accompanying the page proofs.

All published papers become the permanent property of the Korean Society of Menopause and must not be published elsewhere without written permission. A copyright transfer form is readily available on the manuscript submission page (https://www.editorialmanager.com/jmenopausalmed/default2.aspx) and can be completed and submitted electronically. These policies follow the Creative Commons Attribution Non-Commercial License available from the following link: http://creativecommons.org/licenses/by-nc/4.0/.

The full text of JMM has been archived in PubMed Central (PMC). Authors cannot archive pre-print (i.e., pre-refereeing), but they can archive post-print (i.e., final draft post-refereeing). Authors can archive the publisher’s version/PDF.

TAdvertisements from third-party companies or resources may be accessible through our journal's web page. Our journal is a separate entity; we are not responsible or liable for any contents and advertisements available on resources linked to our web page. Advertisements are managed separately from published material, and editorial decisions remain independent from the advertisements.

Editorial board members may submit an article to the journal. When an editorial board member is listed as one of the co-authors, first author, or corresponding author of an article, this must be declared in a "Conflict of Interest” section in the manuscript. He or she will not be involved in the whole review process for clarity and transparency.

JMM allows a paper that has not conducted peer review on a preprint server such as the MedRxiv, researchsquare, and bioRxiv will not be considered as a duplicate publication, provided that the following conditions are met:
1) During submission, authors must acknowledge preprint server deposition and provide any associated accession numbers or Digital Object Identifiers (DOIs) and a link to the preprint in their manuscript and cover letter.
2) Versions of a manuscript that have been altered as a result of the peer review process may not be deposited.
3) The preprint version cannot itself have been indexed in MEDLINE or PubMed.
4) Upon publication, authors are responsible for updating the archived preprint with a DOI and link to the final published version of the article. Work that has been previously published, or is under consideration for publication in another journal, will not be considered.
5) JMM would expect the preprint to be amended after final publication to state “This is an author-created, preprint version of an article accepted for publication in the Journal of Menopausal Medicine (http://www.e-jmm.org).”

There is currently no submission fee for the JMM.

Publication Types

JMM publishes editorials, review articles, original articles, and brief communications

1. Editorials: invited perspectives on an area of menopause, a short dissertation expressing opinions, experiences or a statement regarding a topic of current interest, a question or challenge to an article recently published in JMM, or editorial notice (erratum, revision, addendum etc.)
2. Review articles: menopause research written by an invited expert, a comprehensive review of prior publications related to specific important topics
3. Original articles: full-length reports of basic science or clinical investigations
4. Brief communications: clinical researches on surgical interest or innovation, researches drawing attention to an important clinical situation, researches on unusual clinical phenomena, or researches of a new treatment or complication

General Guidelines

1. The main document with the manuscript text and tables should be prepared in MS Word in English.
2. The manuscript should be written in 12-point font (Times New Roman) and should be double-spaced on an A4-sized (21.0 × 29.7 cm) paper with 2.5-cm margins on the top, bottom, right, and left.
3. Number all pages in sequence, including the Title page, Abstract, Introduction, Materials and Methods, Results, Discussion, Acknowledgment, and References, followed by Figure legends.
4. Reference citations are in Vancouver style. Use [1], [3,4], [6-8] in the main text. References should be listed in the References section in a numerical order.
5. The use of acronyms and abbreviations is discouraged and should be kept to a minimum. When used, they are to be defined on first use, followed by the acronym or abbreviation in parentheses.
6. Units of measure should be presented according to the International System (SI) of Units. All units must be preceded by one space except angle (°), percentage (%), and temperature (°C).
7. Statistical expression: mean and standard deviation should be described as mean ± SD and mean and standard error as mean ± SE. P-values should be described as P < 0.05 or P = 0.002.

Original Articles

Manuscripts will not be accepted for publication unless they meet the following editorial requirements. Manuscripts must include 1) a title page, 2) a structured abstract and keywords, 3) the main text (Introduction, Materials and Methods, Results, Discussion), 4) acknowledgments, 5) references, 6) tables, and 7) figures and figure legends. Each component should begin on a new page in the following sequence.
The maximum length of a manuscript is 4,500 words of body text, excluding the abstract, references, figures, and tables. These articles are limited to 40 references.

1. Title page: Include on the title page: a) complete manuscript title; b) authors’ full names, affiliations, academic degrees and ORCIDs; c) a running title of no longer 10 words; d) name, affiliation, address, phone number, ORCID, and e-mail address of corresponding author(s).
2. Abstract and Keywords: On a separate page, provide an abstract of 250 words or less, organized under the following headings: Objectives, Methods, Results, and Conclusions. Three to five keywords, which should be Medical Subject Headings (MeSH)-authorized words, should be listed just after the abstract in an alphabetical order. The first letter of a keyword should be capitalized (ex: Body mass index, Osteoporosis, Postmenopause).
3. Main Text: Begin the body of the manuscript on a separate page following the abstract. Although not appropriate for some articles, most regular manuscripts should adhere to the following sequence: Introduction, Materials and Methods, Results, Discussion, References, and Figure legends. Cite all tables and illustrations in the text. If a brand name is cited, supply the manufacturer’s name and location (city and state, country).
   
   
   • Introduction: The introduction should supply sufficient background knowledge and information to allow readers to understand and evaluate the value of the study.
   • Materials and Methods: The research plan, the materials (or subjects), and the methods used should be described, in that order. How the disease was confirmed and how subjectivity in observations was controlled should be explained in detail. When the experimental methodology is the main issue of the paper, the process should be described in detail so that the experiment can be recreated as closely as possible. The sources of the apparatus or reagents used should be provided along with the source location (name of company, city, and country). If relevant, information on IRB approval and informed consent should be included. Methods of statistical analysis and criteria for statistical significance should be described. Ensure correct use of the terms sex (when reporting biological factors) and gender (identity, psychosocial or cultural factors). Also, unless inappropriate, report the sex and/or gender of study participants, the sex of animals or cells, and describe the methods used to determine sex and gender. If the study was done involving an exclusive population, for example in only one sex, authors should justify why, except in obvious cases (e.g., endometrial cancer).
   • Results: Results should be presented in logical sequence in the text, tables, and illustrations. The text should not repeat all the data in the tables or figures, but rather describe important points and trends.
   • Discussion: Observations pertaining to the results of the research and other related materials should be interpreted for your readers. Emphasize new and important observations; do not merely repeat the contents in the Introduction or Results. Explain the meaning of the observed opinion along with its limits, and within the limits of the research results, connect the conclusion to the purpose of the research.
   
   
4. Funding: Acknowledge financial support. The usual format for grant support is as follows: "This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korean Government (2014-0009917)." If there was no funding, the following wording should be used: "No funding to declare."
5. Acknowledgments: Any persons that contributed to the study or the manuscript but not meeting the requirements of authorship could be placed here. Acknowledge anyone who provided intellectual assistance, purely technical help (including writing and editing assistance), special equipment or materials, advice, gifts, etc.
6. Conflict of Interest: All authors should declare any financial support or relationship that may pose conflict of interest as “Disclosure Statement” between Acknowledgements and References sections, using the ICMJE format. All authors will be required to complete a conflict of interest disclosure form as part of the initial manuscript submission process. The latest form can be downloaded from here :
   https://e-jmm.org/index.php?body=instructions or https://www.editorialmanager.com/jmenopausalmed/default2.aspx.
7. References: The authors are responsible for the accuracy of the references. Number references in the order of their use in the text; do not alphabetize. Identify references in the text with Arabic numerals in square brackets. If there are more than six authors, name only the first six authors and then use “et al.” Refer to the List of Journals Indexed in Index Medicus for abbreviations of journal names, or access the list at http://www.ncbi.nlm.nih.gov/nlmcatalog/journals. Sample references are given below:

Journal article

• 1.
  Lee JR, Lee D, Park S, Paik EC, Kim SK, Jee BC, et al. Successful in vitro fertilization and embryo transfer after transplantation of cryopreserved ovarian tissue: report of the first Korean case. J Korean Med Sci 2018; 33: e156.
• 2.
  Somayeh K, Samad Z, Parvin B. Flavonoids Fraction of Mespilus Germanica alleviates insulin resistance in metabolic syndrome model of ovariectomized rats via reduction in tumor necrosis factor-α. J Menopausal Med 2018; 24: 169-75.
• 3.
  Jung YW, Jeon YJ, Park HM, Lee BE, Rah H, Lee WS, et al. Association between polymorphisms in renin-angiotensin system genes and primary ovarian insufficiency in Korean women. Menopause 2012. doi: 10.1097/gme.0b013e3182733921

** Addendum: The period should be erased after the address of digital object identifier (DOI).

Book

• 4.
  Spector RE. Cultural diversity in health and illness. 5th ed. Prentice Hall; 2000.

Book chapter

• 5.
  Shifren JL, Schiff I. Menopause. In: Berek JS, editor. Berek & Novak’s gynecology. 14th ed. Philadelphia: Lippincott Williams & Wilkins; 2007. p.1323.
• 6.
  Triffitt JT. The stem cell of the osteoblast. In: Bilezikian JP, Raisz LG, Rodan GA, editors. Principles of bone biology. San Diego, CA: Academic Press; 1996. pp.39-50.

**Authors may omit the city and country of the publishing company.

Website

• 7.
  Korean Statistical Information Service. Population projections and summary indicators for Korea. Seoul: Statistics Korea, 2011 [cited by 2012 Jan 3]. Available
  from: http://kosis.kr/abroad/abroad_01List.jsp?parentId=A.
• 8.
  Tables: Each table should be prepared on a separate page within the manuscript. The tables and they should be titled and numbered in Arabic numerals in the order of their first citation in the text. Each column should have a short heading. Only the first letter of the first word in each row and column should be capitalized. If numerical measurements are given, the unit of measurement should be included in the column heading. The statistical significance of observed differences in data should be indicated with the appropriate statistical analysis. All nonstandard abbreviations must be defined in footnotes. For special remarks, lower case letters in superscripts ^a, ^b, ^c, ^d… should be used.
• 9.
  Figures: Each figure should be submitted either as a TIFF, EPS file, or JPG file. Line art must have a resolution of at least 1,200 dpi, and photographs (ex: radiographs, CT scans) and scanned images must have a resolution of at least 300 dpi. Lettering and identifying marks should be clear, and the type size should be consistent on each figure. Capital letters should be used for specific areas of identification in a figure. Symbols, lettering, and numbering should be distinctly recognizable so that when the figure is reduced for publication, each item will still be legible. Titles and detailed explanations belong in the figure legends, not on the illustrations themselves. Figure legends should not be included in the same file as the figure, but placed instead on a page at the end of the manuscript. Figures should be numbered in the form Fig. 1, Fig. 2, and Fig. 3. Only the first letter of the first word in the title and data should be capitalized. Related figures should be combined into a single figure, with each subfigure denoted by the letters, A, B, C, and so on, following the Arabic number of the main figure (ex: Fig. 1A, Fig. 1B, Fig. 1A-1C). Illustrations of pathological tissues should clearly state the type of stain (ex: H & E, ×400), and the relevant features should be marked with signs or arrows on the picture. The Editorial Committee may request that hand-drawn illustrations be redrawn by a graphic designer.

**Addendum:
- Authors can omit the location of the company producing reagents, equipment, devices, software, etc., i.e. Gardasil 9, Merck & Co.

Editorials

Editorial topics include active areas of research, fresh insights, and debates in all fields of menopause. Editorials should not exceed 2,000 words, excluding references, tables, and figures.

Review Articles

Reviews are invited by the editor and should be comprehensive analyses of specific topics. The manuscript for a review article should be organized in the following sequence: title page, abstract and keywords, main text (Introduction, Contents, Conclusion), acknowledgments (if necessary), references, tables, and figure legends. Manuscripts are limited to 5,000 words of text and include a 250-word summary in place of an unstructured abstract. References should not exceed 100.

Brief Communications

Brief Communications should present focused, new clinical or investigational observations. The manuscript for a brief communication should be organized in the following sequence: title page, abstract and keywords, main text, acknowledgments (if necessary), references, tables, and figure legends. The manuscript should not exceed 2,000 words and the number of references is limited to 15. The abstract should be unstructured and should not exceed 250 words.

1. Manuscript is written in MS Word, is double-spaced in 12-point Times New Roman, and has 2.5-cm margins at both sides, top, and bottom.
2. All pages are numbered consecutively starting from the title page.
3. Abstract does not exceed 250 words in English for an original article, review article, brief communication or case report. Keywords are MeSH-approved terms.
4. References are accurate, complete, and in numerical order as they appear in the text, with only the first six authors listed.
5. All tables and figures are cited in the text.
6. A cover letter is provided, stating the scientific significance of the study, stating that the materials have not been published previously and will not be submitted for publication elsewhere, and stating conflicts of interest of all listed authors, if any.
7. Each author has read the manuscript and agrees with this submission
8. Others: A copyright Transfer Agreement form and a Conflict of Interest form should be included in the manuscript.

Notice: These recently revised instructions for authors will be applied beginning with the April 2023 issue.